JP2016529213A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529213A5
JP2016529213A5 JP2016522133A JP2016522133A JP2016529213A5 JP 2016529213 A5 JP2016529213 A5 JP 2016529213A5 JP 2016522133 A JP2016522133 A JP 2016522133A JP 2016522133 A JP2016522133 A JP 2016522133A JP 2016529213 A5 JP2016529213 A5 JP 2016529213A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
seq
set forth
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529213A (ja
JP6563389B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000673 external-priority patent/WO2014205501A1/en
Publication of JP2016529213A publication Critical patent/JP2016529213A/ja
Publication of JP2016529213A5 publication Critical patent/JP2016529213A5/ja
Application granted granted Critical
Publication of JP6563389B2 publication Critical patent/JP6563389B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522133A 2013-06-27 2014-06-27 Il−21結合タンパク質及びその使用 Expired - Fee Related JP6563389B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013902377 2013-06-27
AU2013902377A AU2013902377A0 (en) 2013-06-27 A super-agonist monoclonal antibody to human IL-21 and its application in immunomodulation
PCT/AU2014/000673 WO2014205501A1 (en) 2013-06-27 2014-06-27 Il-21 binding proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2016529213A JP2016529213A (ja) 2016-09-23
JP2016529213A5 true JP2016529213A5 (enExample) 2018-11-01
JP6563389B2 JP6563389B2 (ja) 2019-08-21

Family

ID=52140667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522133A Expired - Fee Related JP6563389B2 (ja) 2013-06-27 2014-06-27 Il−21結合タンパク質及びその使用

Country Status (8)

Country Link
US (3) US10077301B2 (enExample)
EP (1) EP3013858B1 (enExample)
JP (1) JP6563389B2 (enExample)
CN (1) CN105579470B (enExample)
AU (1) AU2014302028B2 (enExample)
CA (1) CA2915882C (enExample)
ES (1) ES2898650T3 (enExample)
WO (1) WO2014205501A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205501A1 (en) 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
JP6872756B2 (ja) * 2016-01-12 2021-05-19 国立大学法人千葉大学 抗Myl9抗体
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN119290543B (zh) * 2024-12-13 2025-03-21 天津医科大学总医院空港医院 一种同时检测淋巴组织中il-6、il-21与t细胞cd4表面分子的试剂盒及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
BRPI0510996A (pt) * 2004-05-19 2007-12-04 Wyeth Corp métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2006105538A2 (en) * 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
JP5322653B2 (ja) 2005-11-28 2013-10-23 ザイモジェネティクス, インコーポレイテッド Il−21アンタゴニスト
WO2007109742A2 (en) 2006-03-21 2007-09-27 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
WO2008112543A2 (en) * 2007-03-09 2008-09-18 Wyeth Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences
JP5745274B2 (ja) * 2007-12-07 2015-07-08 ザイモジェネティクス, インコーポレイテッド 抗ヒトil−21モノクローナル抗体
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体
WO2014205501A1 (en) 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof

Similar Documents

Publication Publication Date Title
TWI821474B (zh) Cd3抗體及其藥物用途
CN112969476B (zh) 多特异性蛋白分子
JP2016529213A5 (enExample)
JP2020508655A5 (enExample)
JP2020525032A5 (enExample)
JP2020063262A5 (enExample)
JP2017504578A5 (enExample)
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2018517431A5 (enExample)
CN111417653A (zh) Cd47抗原结合分子
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2020531043A (ja) 抗4−1bb抗体とその作製及び使用方法
JP2019524693A5 (enExample)
JP2017535257A5 (enExample)
JP2019532619A5 (enExample)
JP2018527919A5 (enExample)
JP2015163068A5 (enExample)
JP2014518615A5 (enExample)
JP2013545455A5 (enExample)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2013506428A5 (enExample)
JP2017504577A5 (enExample)
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2019512207A5 (enExample)
JP2017537082A5 (enExample)